Part 1, The Top CBD Cannabis Studies of 2017

The Top CBD Cannabis Studies of 2017

The past year was important for proponents of medical cannabis. Those seeking to remove cannabis’ Schedule I status are now armed with even more evidence for its medicinal and wellness benefits from a combination of human and rodent studies. From benefits in epilepsy, autism, and beyond, here are some of 2017’s biggest medical cannabis news stories. This installment covers insights relating to CBD, but tune in to the second part of this series for more discoveries uncovered in 2017.

Cannabidiol (CBD) passes stage 3 clinical trial for treatment of epilepsy in children.

Source: New England Journal of Medicine, May 2017

This one was big. One of the greatest limitations in the medicinal cannabis field is the lack of randomized double-blinded studies, the standard in clinical research. This limitation is often the basis of the opposition’s argument that there’s no strong evidence to support

... read more at: https://www.leafly.com/news/health/top-cbd-cannabis-research-2017

by